Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke

Stroke

Volumn 30, Issue 10, 1999, Pages 2038-2042

  Dyker, A G ^a   Edwards, K R ^b   Fayad, P B ^c   Hormes, J T ^d   Lees, K R ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b Southwestern Vermont Medical Center   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Marietta Neurologic Associates   (United States)

Author keywords

Aptiganel; Glutamate antagonists; Neuroprotection; NMDA antagonists; Stroke, acute

Indexed keywords

APTIGANEL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; NEUROPROTECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; VERTIGO; VISUAL DISORDER;

EID: 0032824132     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.10.2038     Document Type: Article

References (11)

1. McCulloch J. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. Br J Clin Pharmacol. 1992; 34:106-114.
2. Minematsu K, Fisher M, Li L, Davis MA, Knapp AG, Cotter RE, McBurney RN, Sotak CH. Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI. Neurology. 1993;43:397-403.
3. Cohen RA, Hasegawa Y, Fisher M. Effects of a novel NMDA receptor antagonist on experimental stroke quantitatively assessed by spectral EEG and infarct volume. Neurol Res. 1994;16:443-448.
4. Aronowski J, Ostrow P, Samways E, Strong R, Zivin JA, Grotta JC. Graded bioassay for demonstration of brain rescue from experimental acute ischemia in rats. Stroke. 1994;25:2235-2240.
5. Muir KW, Grosset DG, Gamzu E, Lees KR. Pharmacological effects of the non-competitive NMDA antagonist CNS1102 in normal volunteers. Br J Clin Pharmacol. 1994;38:33-38.
6. Fisher M, for the CNS 1102-003 Investigators. Cerestat™, (CNS 1102) a non-competitive NMDA antagonist, in ischemic stroke patients: dose-escalating safety study. Cerebrovasc Dis. 1994;4:245. Abstract.
7. Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale: extension to non-neurologists in the context of a clinical trial. Stroke. 1997;28:307-310.
8. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61-65.
9. Muir KW, Grosset DG, Lees KR. Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers. Clin Neuropharmacol. 1997;20:311-321.
10. Wahlgren NG, MacMahon DG, De Keyser J, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis. 1994; 4:204-210.
11. Squire IB, Lees KR, Pryse-Phillips W, Kertesz A, Bamford J. The effects of lifarizine in acute cerebral infarction: a pilot safety study. Cerebrovasc Dis. 1996;6:156-160.